Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population

Shuang ZHANG; Xiaohui LIU; Gang WANG; Li ZHANG; Yunjie ZHU; Jian WU; Yali LIU; Jing ZHANG

doi:10.3969/j.issn.1001-5256.2022.03.011

Volume 38 Issue 3

Mar. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(3): 547-552

PDF( 2059 KB)

Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population

DOI: 10.3969/j.issn.1001-5256.2022.03.011

Shuang ZHANG¹,
Xiaohui LIU¹,
Gang WANG²,
Li ZHANG²,
Yunjie ZHU³,
Jian WU³,
Yali LIU^{1
,
,
,},
Jing ZHANG^{1
,
,
,}

1.
The Third Unit, Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
2.
Department of General Practice, Menkuang Hospital, Beijing Jingmei Group General Hospital, Beijing 102399, China
3.
School of Kinesiology and Health, Capital University of Physical Education and Sports, Beijing 100191, China

Research funding:

Research Project of Beijing Research Association for Chronic Diseases Control and Health Education (BJMB0012021025002)

More Information

Corresponding author: LIU Yali, ericliudoc@ccmu.edu.cn(ORCID:0000-0002-1249-6010); ZHANG Jing, zjyouan@ccmu.edu.cn(ORCID:0000-0002-3082-8330)
Received Date: 2021-08-03
Accepted Date: 2021-09-09
Published Date: 2022-03-20

Abstract

Abstract

Objective To investigate the population differences of the newly named "metabolic associated fatty liver disease" (MAFLD) and the former name "nonalcoholic fatty liver disease" (NAFLD). Methods From November 2020 to January 2021, a cross-sectional survey was conducted among 624 elderly individuals aged above 65 years in a community in Beijing, China, and related data were collected, including demographic data, past history, laboratory markers, liver ultrasound, and liver elasticity. According to the presence or absence of fatty liver based on ultrasonic diagnosis, the individuals were divided into fatty liver group with 389 individuals and non-fatty liver group with 235 individuals. The independent samples t-test was used for comparison of normally distributed continuous data between the two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between the two groups; the chi-square test was used for comparison of categorical data between the two groups. Results Among the 389 patients with fatty liver, 387(99.5%) were diagnosed with MAFLD and 368(94.6%) were diagnosed with NAFLD, and there were 19 patients with a history of heavy alcohol consumption and 2 with positive surface antigen. A total of 366 patients met the diagnostic criteria for both MAFLD and NAFLD, accounting for 94.6% of the MAFLD patients and 99.5% of the NAFLD patients. Compared with the non-fatty liver group, the MAFLD group had significant increases in body mass index (BMI) (t=-11.228, P < 0.05), waist circumference (Z=-8.532, P < 0.05), hip circumference (Z=-6.449, P < 0.05), waist-hip ratio (Z=-5.708, P < 0.05), alanine aminotransferase (Z=-5.027, P < 0.05), aspartate aminotransferase (Z=-2.880, P < 0.05), platelet count (t=-3.623, P < 0.05), triglyceride (Z=-8.489, P < 0.05), fasting blood glucose (Z=-3.516, P < 0.05), HbA1c (Z=-2.884, P < 0.05), Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (Z=-0.394, P < 0.05), high-sensitivity C-reactive protein (Z=-4.912, P < 0.05), controlled attenuation parameter (CAP) (t=13.744, P < 0.05), and liver stiffness measurement (LSM) (Z=-7.69, P < 0.05), as well as a significant reduction in high-density lipoprotein cholesterol (HDL-C) (t=6.348, P < 0.001). Meanwhile, MAFLD patients had more metabolic associated diseases, such as overweight, obesity, central obesity, dyslipidemia, and hypertension (χ²=9.978, 65.472, 36.571, 9.797, and 5.128, all P < 0.05). In the MAFLD group, 30.7% of the patients had non-obese fatty liver disease (BMI < 25 kg/m²), and 11.1% had lean fatty liver disease (BMI < 23 kg/m²); compared with the obese MAFLD patients, the non-obese MAFLD patients had significantly lower age (Z=-3.042, P < 0.05), BMI (Z=-15.705, P < 0.05), waist circumference (Z=-9.589, P < 0.05), hip circumference (Z=-10.275, P < 0.05), HOMA-IR (Z=-2.081, P < 0.05), CAP (t=-3.468, P < 0.05), LSM (Z=-3.630, P < 0.05), and NAFLD fibrosis score (t=-4.433, P < 0.05). According to LSM value, advanced liver fibrosis accounted for 3.6% of the MAFLD population, and 10% of the MAFLD population could not be excluded for advanced liver fibrosis. Conclusion The diagnosis of MAFLD can basically cover the NAFLD population in the elderly people, and it is supposed that MAFLD can almost directly replace the concept of NAFLD in similar populations. However, further studies are needed to investigate its application in other populations.
- Metabolic Associated Fatty Liver Disease,
- Non-alcoholic Fatty Liver Disease,
- Hospitals, Community,
- Cross-Sectional Studies

FullText(HTML)

References(10)

References

[1]	ESLAM M, SANYAL AJ, GEORGE J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312.
[2]	LIN S, HUANG J, WANG M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40(9): 2082-2089. DOI: 10.1111/liv.14548.
[3]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[4]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[5]	NEWSOME PN, CRAMB R, DAVISON SM, et al. Guidelines on the management of abnormal liver blood tests[J]. Gut, 2018, 67(1): 6-19. DOI: 10.1136/gutjnl-2017-314924.
[6]	NAN Y, AN J, BAO J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol, 2021, 75(2): 454-461. DOI: 10.1016/j.jhep.2021.05.003.
[7]	WONG VW, WONG GL, WOO J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2161-2171. e5. DOI: 10.1016/j.cgh.2020.10.046.
[8]	YAMAMURA S, ESLAM M, KAWAGUCHI T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD[J]. Liver Int, 2020, 40(12): 3018-3030. DOI: 10.1111/liv.14675.
[9]	YE Q, ZOU B, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(8): 739-752. DOI: 10.1016/S2468-1253(20)30077-7.
[10]	LI YY, XIE ZY. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043. 李洋洋, 谢正元. 非肥胖型非酒精性脂肪性肝病的病因及治疗进展[J]. 临床肝胆病杂志, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043.

Relative Articles

[1]	Xiaodong ZHOU, Na TIAN, Minghua ZHENG. Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2336-2339. doi: 10.3969/j.issn.1001-5256.2023.10.010
[2]	Mengru YANG, Rui HAN. Research advances in the relationship between nonalcoholic fatty liver disease and chronic kidney disease[J]. Journal of Clinical Hepatology, 2022, 38(11): 2586-2591. doi: 10.3969/j.issn.1001-5256.2022.11.030
[3]	Xuelian GU, Junfeng LI, Xiaorong MAO. Research advances in nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(1): 196-200. doi: 10.3969/j.issn.1001-5256.2022.01.034
[4]	Xiaochen LU, Hongmei HAN. Research advances in in vitro models for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 201-205. doi: 10.3969/j.issn.1001-5256.2022.01.035
[5]	Yunxia WU, Chengliang LI, Xiaolei LI, Zhaoxiao LUO, Tianshun REN. Correlation between cardiometabolic index and metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(10): 2247-2251. doi: 10.3969/j.issn.1001-5256.2022.10.010
[6]	Luying ZHU, Yuchen LI, Lihua DENG, Jingtong WANG. Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2215-2219. doi: 10.3969/j.issn.1001-5256.2021.09.043
[7]	Gaiya GAO, Sha LI, Jingdong XUE, Yanyan BAI, Youyi HUI. Traditional Chinese medicine syndrome types and syndrome elements of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(1): 89-93. doi: 10.3969/j.issn.1001-5256.2021.01.018
[8]	Yuting LUAN, Zhongming HUANG, Wenjuan SHEN, Minghao HA, Zhibing XU. Research advances in metabolomics in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 943-946. doi: 10.3969/j.issn.1001-5256.2021.04.047
[9]	Qianqian XIAO, Mengyu WANG, Jiangao FAN. Brief introduction of APASL clinical practice guidelines on metabolic associated fatty liver disease (Treatment Part)[J]. Journal of Clinical Hepatology, 2021, 37(1): 41-45. doi: 10.3969/j.issn.1001-5256.2021.01.009
[10]	Junzhao YE, Yansong LIN, Bihui ZHONG. Research advances in dietary intervention in the treatment of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(3): 709-713. doi: 10.3969/j.issn.1001-5256.2021.03.042
[11]	Xiao WeiSong, Le YingYu, Ceng ShengLan, Tan XiaoBin, Wu Cong, Mao DeWen. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(8): 1874-1879. doi: 10.3969/j.issn.1001-5256.2020.08.043
[12]	A RuHan, Jia HaiYan, Ding YanHua, Niu JunQi. Research advances in nonalcoholic fatty liver disease in lean individuals[J]. Journal of Clinical Hepatology, 2020, 36(5): 1154-1159. doi: 10.3969/j.issn.1001-5256.2020.05.046
[13]	Xue Rui, Fan JianGao. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1224-1227. doi: 10.3969/j.issn.1001-5256.2020.06.007
[14]	Gao Xin. New thoughts about renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1201-1204. doi: 10.3969/j.issn.1001-5256.2020.06.001
[15]	Ceng Jing, Fan JianGao. Clinical significance of renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1205-1207. doi: 10.3969/j.issn.1001-5256.2020.06.002
[16]	LIU YingYing, LIU YuPing, LIU YouRen, SUN Ping. Implementation of aerobic exercise intervention in patients with metabolic associated fatty liver disease:A prospective study[J]. Journal of Clinical Hepatology, 2020, 36(11): 2467-2472. doi: 10.3969/j.issn.1001-5256.2020.11.014
[17]	Gui WenFang, Zhu QingJing, Yang Ling. Research advances in nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(12): 2693-2697. doi: 10.3969/j.issn.1001-5256.2018.12.040
[18]	Chen YanZhen, Chen ChengLiang, Tian Xing, Jiao Jian. Research advances in animal models based on the pathogenesis and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2457-2461. doi: 10.3969/j.issn.1001-5256.2017.12.046
[19]	Liu JiaQi, Zhou ShaoMing. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2453-2456. doi: 10.3969/j.issn.1001-5256.2017.12.045

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	梁宝怡，沈天然，郑秋潼，谢灵香，喻陆，陈青松. 老年人群残余胆固醇与代谢相关脂肪性肝病的关联性和剂量反应关系的研究. 现代预防医学. 2025(03): 520-525 .
2.	陈亮，潘佰灵，徐丽伟，徐婷. 超声诊断仪联合内脏脂肪检测仪在非酒精性脂肪肝中的诊断价值. 医疗装备. 2024(01): 22-24 .
3.	吴彬彬，徐小琴，顾星星，解其华. 脂肪肝诊断中ElastPQ弹性成像技术检测肝硬度与肝纤维化评分及FIB-4指数的相关性分析. 肝脏. 2024(01): 73-76 .
4.	蒋传林. 酒精性肝炎患者自噬相关蛋白表达水平辅助肝纤维化程度诊断的临床价值. 中国肝脏病杂志(电子版). 2024(04): 57-61 .
5.	朱凯，杨磊，周青，马雪儿，李琴，何晓萱，杨雪霞，蔡雯. PNPLA3和FABP1基因甲基化与代谢相关脂肪性肝病相关性分析. 肝脏. 2023(02): 207-213 .
6.	王艳红. 非酒精性脂肪性肝病患者血清ALT、AST与肝纤维化的关系. 中国现代药物应用. 2023(09): 15-18 .
7.	包萨如拉，杜晓旭，戈宏焱. 幽门螺杆菌感染联合传统危险因素预测代谢相关脂肪性肝病发生风险的价值分析. 临床肝胆病杂志. 2023(06): 1318-1324 . 本站查看
8.	鲁旭娟，张慧萍. 非酒精性脂肪肝患者血脂、血糖和肝功能联合检测及其临床意义. 贵州医药. 2023(06): 896-897 .
9.	林怀德，周稳兰，朱蔚岗. 微小RNA-34a在代谢相关脂肪性肝病中的价值. 中国临床医生杂志. 2023(09): 1036-1039 .
10.	朱韶华. 基于Web of Science数据库的2012-2021年肥胖症研究在流行病学领域的文献计量分析. 医学信息. 2022(24): 40-45 .
11.	张志娇，姜梓萌，陈宇航，黄华，赵公芳. 脂肪肝诊断标准更名后饮酒在临床分层管理中的价值. 现代消化及介入诊疗. 2022(12): 1519-1522 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (676) PDF downloads(84)

Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population

DOI: 10.3969/j.issn.1001-5256.2022.03.011